17,201 Shares in Bioventus Inc. (NYSE:BVS) Acquired by Dynamic Technology Lab Private Ltd

Dynamic Technology Lab Private Ltd bought a new stake in shares of Bioventus Inc. (NYSE:BVS) in the fourth quarter, HoldingsChannel.com reports. The firm bought 17,201 shares of the company’s stock, valued at approximately $181,000.

A number of other hedge funds have also added to or reduced their stakes in BVS. Charles Schwab Investment Management Inc. grew its holdings in shares of Bioventus by 38.9% in the third quarter. Charles Schwab Investment Management Inc. now owns 390,162 shares of the company’s stock worth $4,662,000 after acquiring an additional 109,359 shares during the period. JPMorgan Chase & Co. grew its stake in shares of Bioventus by 228.3% during the 3rd quarter. JPMorgan Chase & Co. now owns 253,740 shares of the company’s stock valued at $3,032,000 after purchasing an additional 176,442 shares during the period. State Street Corp grew its stake in shares of Bioventus by 38.8% during the 3rd quarter. State Street Corp now owns 676,501 shares of the company’s stock valued at $8,084,000 after purchasing an additional 189,216 shares during the period. Barclays PLC increased its position in shares of Bioventus by 24.2% during the 3rd quarter. Barclays PLC now owns 50,654 shares of the company’s stock valued at $606,000 after purchasing an additional 9,854 shares during the last quarter. Finally, Geode Capital Management LLC lifted its stake in shares of Bioventus by 7.5% in the 3rd quarter. Geode Capital Management LLC now owns 940,496 shares of the company’s stock worth $11,241,000 after purchasing an additional 65,374 shares during the period. 62.94% of the stock is currently owned by hedge funds and other institutional investors.

Bioventus Trading Down 1.2 %

BVS stock opened at $7.48 on Friday. The company has a market capitalization of $612.94 million, a price-to-earnings ratio of -12.26 and a beta of 0.92. The company has a debt-to-equity ratio of 1.85, a current ratio of 1.41 and a quick ratio of 0.99. Bioventus Inc. has a 1-year low of $3.90 and a 1-year high of $14.38. The business has a 50 day simple moving average of $9.59 and a two-hundred day simple moving average of $10.73.

Analyst Ratings Changes

BVS has been the subject of a number of research reports. Canaccord Genuity Group reaffirmed a “buy” rating and set a $15.00 target price on shares of Bioventus in a report on Monday, March 17th. JPMorgan Chase & Co. upgraded Bioventus from an “underweight” rating to a “neutral” rating and upped their price objective for the stock from $12.00 to $13.00 in a research note on Tuesday, December 17th.

Insider Buying and Selling

In related news, SVP Anthony D’adamio sold 4,380 shares of the company’s stock in a transaction on Tuesday, February 18th. The shares were sold at an average price of $10.19, for a total transaction of $44,632.20. Following the sale, the senior vice president now owns 118,178 shares of the company’s stock, valued at $1,204,233.82. This represents a 3.57 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, CFO Mark Leonard Singleton sold 5,479 shares of the stock in a transaction on Monday, March 24th. The shares were sold at an average price of $9.79, for a total transaction of $53,639.41. Following the transaction, the chief financial officer now owns 131,963 shares of the company’s stock, valued at $1,291,917.77. This trade represents a 3.99 % decrease in their position. The disclosure for this sale can be found here. Over the last three months, insiders have sold 46,161 shares of company stock worth $436,364. Corporate insiders own 32.90% of the company’s stock.

About Bioventus

Bioventus Inc, a medical device company, focuses on developing and commercializing treatments that engage and enhance the body's natural healing process in the United States and internationally. The company's product portfolio includes pain treatments, which comprise non-surgical pain injection therapies, as well as peripheral nerve stimulation products, such as Durolane, GELSYN-3, and SUPARTZ for the treatment of knee osteoarthritis and Stimrouter to treat chronic peripheral pain.